Table 4. Characteristics of claims filed according to deliberation results.
| Characteristic | Compensated (n = 318) | Dismissed (n = 151) |
|---|---|---|
| Male sex | 208 (65.4) | 79 (52.3) |
| Age group (yr) | ||
| 0-3 | 248 (78.0) | 45 (29.8) |
| 4-18 | 23 (7.2) | 24 (15.9) |
| 19-64 | 18 (5.7) | 19 (12.6) |
| ≥ 65 | 29 (9.1) | 63 (41.7) |
| Vaccine typea) | ||
| BCG | 225 (70.8) | 10 (6.6) |
| Influenzab) | 28 (8.8) | 62 (41.1) |
| PPV23 | 27 (8.5) | 28 (18.5) |
| DTaP | 13 (4.1) | 27 (17.9) |
| JEV | 8 (2.5) | 12 (7.9) |
| HepB | 8 (2.5) | 6 (4.0) |
| Time interval between vaccination and symptoms (day) | ||
| 0 | 25 (7.9) | 54 (35.8) |
| 1-2 | 40 (12.6) | 45 (29.8) |
| 3-7 | 14 (4.4) | 20 (13.2) |
| 8-14 | 6 (1.9) | 8 (5.3) |
| 15-30 | 26 (8.2) | 11 (7.3) |
| 31-60 | 37 (11.6) | 6 (4.0) |
| > 60 | 170 (53.5) | 7 (4.6) |
| Classification of diagnosis | ||
| Infectious disease | 263 (82.7) | 27 (17.9) |
| Neurological disease | 26 (8.2) | 54 (35.8) |
| Skin, soft tissue, and musculoskeletal disease | 9 (2.8) | 10 (6.6) |
| Allergic reaction | 9 (2.8) | 6 (4.0) |
| Nonspecific systemic symptoms | 6 (1.9) | 18 (11.9) |
| Miscellaneousc) | 5 (1.6) | 36 (23.8) |
| Underlying condition | ||
| No | 245 (77.0) | 81 (53.6) |
| Yes | 48 (15.1) | 63 (41.7) |
| Unknown | 25 (7.9) | 7 (4.6) |
Values are presented as numbers (%).
BCG, bacillus Calmette-Guerin vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; DTaP, diphtheria, tetanus, and pertussis vaccine; JEV, Japanese encephalitis virus vaccine; HepB, hepatitis B vaccine.
a)Includes both single vaccination and simultaneous administration with other vaccines.
b)Includes 25 cases of swine influenza vaccine.
c)Includes respiratory, gastrointestinal, cardiovascular, and hematologic disease.